Connick, Peter https://orcid.org/0000-0002-3892-8037
De Angelis, Floriana
Parker, Richard A
Plantone, Domenico
Doshi, Anisha
John, Nevin
Stutters, Jonathan
MacManus, David
Prados Carrasco, Ferran
Barkhof, Frederik
Ourselin, Sebastien
Braisher, Marie
Ross, Moira
Cranswick, Gina
Pavitt, Sue H
Giovannoni, Gavin
Gandini Wheeler-Kingshott, Claudia Angela
Hawkins, Clive
Sharrack, Basil
Bastow, Roger
Weir, Christopher J
Stallard, Nigel
Chandran, Siddharthan
Chataway, Jeremy https://orcid.org/0000-0001-7286-6901
Clinical trials referenced in this document:
Documents that mention this clinical trial
EXPLORING COGNITION IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
https://doi.org/10.1136/jnnp-2016-315106.129
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjopen-2018-021944
Brain reserve and physical disability in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjno-2024-000670
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
https://doi.org/10.1136/jnnp-2024-334801
RECRUITMENT IN MULTIPLE SCLEROSIS TRIALS: THE MS-SMART EXPERIENCE
https://doi.org/10.1136/jnnp-2016-315106.128
Documents that mention this clinical trial
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT (Results)
https://doi.org/10.3310/eme07030
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjopen-2018-021944
Documents that mention this clinical trial
EXPLORING COGNITION IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
https://doi.org/10.1136/jnnp-2016-315106.129
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjopen-2018-021944
Brain reserve and physical disability in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjno-2024-000670
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
https://doi.org/10.1136/jnnp-2024-334801
RECRUITMENT IN MULTIPLE SCLEROSIS TRIALS: THE MS-SMART EXPERIENCE
https://doi.org/10.1136/jnnp-2016-315106.128
Documents that mention this clinical trial
EXPLORING COGNITION IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
https://doi.org/10.1136/jnnp-2016-315106.129
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjopen-2018-021944
Brain reserve and physical disability in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjno-2024-000670
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
https://doi.org/10.1136/jnnp-2024-334801
RECRUITMENT IN MULTIPLE SCLEROSIS TRIALS: THE MS-SMART EXPERIENCE
https://doi.org/10.1136/jnnp-2016-315106.128
Documents that mention this clinical trial
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT (Results)
https://doi.org/10.3310/eme07030
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjopen-2018-021944